FDA — authorised 20 February 1953
- Marketing authorisation holder: HOSPIRA
- Status: approved
🇺🇸 M.V.I. Pediatric in United States
FDA authorised M.V.I. Pediatric on 20 February 1953
Marketing authorisations
FDA — authorised 6 April 1983
- Application: NDA018920
- Marketing authorisation holder: HOSPIRA
- Local brand name: M.V.I. PEDIATRIC
- Indication: FOR SOLUTION — INTRAVENOUS
- Status: approved
M.V.I. Pediatric in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is M.V.I. Pediatric approved in United States?
Yes. FDA authorised it on 20 February 1953; FDA authorised it on 6 April 1983.
Who is the marketing authorisation holder for M.V.I. Pediatric in United States?
HOSPIRA holds the US marketing authorisation.